Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomide

Maher, 2001, Malignant glioma: Genetics and biology of a grave matter, Genes Dev, 15, 1311, 10.1101/gad.891601

Lassman, 2004, Molecular biology of gliomas, Curr Neurol Neurosci Rep, 4, 228, 10.1007/s11910-004-0043-3

Wen, 2008, Malignant gliomas in adults, N Engl J Med, 359, 492, 10.1056/NEJMra0708126

Gladson, 2010, The pathobiology of glioma tumors, Annu Rev Pathol, 5, 33, 10.1146/annurev-pathol-121808-102109

Furnari, 2007, Malignant astrocytic glioma: Genetics, biology, and paths to treatment, Genes Dev, 21, 2683, 10.1101/gad.1596707

Nagasawa, 2012, Temozolomide and other potential agents for the treatment of glioblastoma multiforme, Neurosurg Clin N Am, 23, 307, 10.1016/j.nec.2012.01.007

Omuro, 2013, Glioblastoma and other malignant gliomas: A clinical review, JAMA, 310, 1842, 10.1001/jama.2013.280319

Chamberlain, 2010, Temozolomide: Therapeutic limitations in the treatment of adult high-grade gliomas, Expert Rev Neurother, 10, 1537, 10.1586/ern.10.32

Pardo, 2014, The roles of K (+) channels in cancer, Nat Rev Cancer, 14, 39, 10.1038/nrc3635

Pardo, 1999, Oncogenic potential of EAG K(+) channels, EMBO J, 18, 5540, 10.1093/emboj/18.20.5540

Hemmerlein, 2006, Overexpression of Eag1 potassium channels in clinical tumours, Mol Cancer, 5, 41, 10.1186/1476-4598-5-41

Patt, 2004, Expression of ether à go-go potassium channels in human gliomas, Neurosci Lett, 368, 249, 10.1016/j.neulet.2004.07.001

Hermisson, 2006, O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells, J Neurochem, 96, 766, 10.1111/j.1471-4159.2005.03583.x

Kim, 2014, A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival, ACS Nano, 8, 5494, 10.1021/nn5014484

Lin, 2011, Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel, PLoS One, 6, e20362, 10.1371/journal.pone.0020362

Essmann, 2012, Translational approaches targeting the p53 pathway for anticancer therapy, Br J Pharmacol, 165, 328, 10.1111/j.1476-5381.2011.01570.x

Pardo, 2008, EAG1: An emerging oncological target, Cancer Res, 68, 1611, 10.1158/0008-5472.CAN-07-5710

Gavrilova-Ruch, 2002, Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells, J Membr Biol, 188, 137, 10.1007/s00232-001-0181-3

García-Ferreiro, 2004, Mechanism of block of hEag1 K+ channels by imipramine and astemizole, J Gen Physiol, 124, 301, 10.1085/jgp.200409041

Roy, 2008, Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7, Oncol Rep, 19, 1511

Gómez-Varela, 2007, Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity, Cancer Res, 67, 7343, 10.1158/0008-5472.CAN-07-0107

Burnett, 2012, RNA-based therapeutic: Current progress and future prospects, Chem Biol, 19, 60, 10.1016/j.chembiol.2011.12.008

Weber, 2006, Silencing the activity and proliferative properties of the human EagI potassium channel by RNA interference, J Biol Chem, 281, 13030, 10.1074/jbc.M600883200

Cunha, 2013, RNA interference with EAG1 enhances interferon gamma injury to glioma cells in vitro, Anticancer Res, 33, 865

Kane, 2010, Interferon-gamma in brain tumor immunotherapy, Neurosurg Clin N Am, 21, 77, 10.1016/j.nec.2009.08.011

Mareschi, 2006, Neural differentiation of human mesenchymal stem cells: Evidence for expression of neural markers and each K+ channel type, Exp Hematol, 34, 1563, 10.1016/j.exphem.2006.06.020

Kwon, 2009, Identification of novel reference genes using multiplatform expression data and their validation for quantitative gene expression analysis, PLoS One, 4, e6162, 10.1371/journal.pone.0006162

Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method, Methods, 25, 402, 10.1006/meth.2001.1262

Kunzelmann, 2005, Ion channels and cancer, J Membr Biol, 205, 159, 10.1007/s00232-005-0781-4

Kondratskyi, 2015, Ion channels in the regulation of apoptosis, Biochim Biophys Acta, 1848, 2532, 10.1016/j.bbamem.2014.10.030

Lang, 2005, Ion channels in cell proliferation and apoptotic cell death, J Membr Biol, 205, 147, 10.1007/s00232-005-0780-5

Menéndez, 2012, Frequent aberrant expression of the human ether à go-go (hEAG1) potassium channel in head and neck cancer: Pathobiological mechanisms and clinical implications, J Mol Med (Berl), 90, 1173, 10.1007/s00109-012-0893-0

Ding, 2007, Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines, World J Gastroenterol, 13, 1257, 10.3748/wjg.v13.i8.1257

Ousingsawat, 2007, Expression of voltage-gated potassium channels in human and mouse colonic carcinoma, Clin Cancer Res, 13, 824, 10.1158/1078-0432.CCR-06-1940

Ding, 2007, Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines, Med Oncol, 24, 345, 10.1007/s12032-007-0015-y

Ortiz, 2011, Eag1 potassium channels as markers of cervical dysplasia, Oncol Rep, 26, 1377

Agarwal, 2010, The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia, Mol Cancer, 9, 18, 10.1186/1476-4598-9-18

Ufartes, 2013, Behavioural and functional characterization of Kv10.1 (Eag1) knockout mice, Hum Mol Genet, 22, 2247, 10.1093/hmg/ddt076

García-Quiroz, 2011, Astemizole: An old anti-histamine as a new promising anti-cancer drug, Anticancer Agents Med Chem, 11, 307, 10.2174/187152011795347513

Martínez, 2015, Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival, BMC Cancer, 15, 839, 10.1186/s12885-015-1848-y

de Guadalupe Chávez-López, 2015, Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC, Tumour Biol, 36, 6149, 10.1007/s13277-015-3299-0

García-Quiroz, 2014, In vivo dual targeting of the oncogenic Ether-à-go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors, BMC Cancer, 14, 745, 10.1186/1471-2407-14-745

de Guadalupe Chávez-López, 2014, Antiproliferative and proapoptotic effects of astemizole on cervical cancer cells, Int J Gynecol Cancer, 24, 824, 10.1097/IGC.0000000000000151

de Abajo, 1999, Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs, Br J Clin Pharmacol, 47, 307, 10.1046/j.1365-2125.1999.00885.x

Oppenheimer, 2002, Next generation antihistamines: Therapeutic rationale, accomplishments and advances, Expert Opin Investig Drugs, 11, 807, 10.1517/13543784.11.6.807

González, 1998, Pharmacokinetic overview of oral second-generation H1 antihistamines, Int J Clin Pharmacol Ther, 36, 292

vanTellingen, 2015, Overcoming the blood-brain tumor barrier for effective glioblastoma treatment, Drug Resist Updat, 19, 1, 10.1016/j.drup.2015.02.002

Wu, 2012, Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) inhibition of human osteosarcoma angiogenesis via VEGF/PI3K/AKT signaling, Int J Mol Sci, 13, 12573, 10.3390/ijms131012573

Hui, 2015, Knockdown of Eag1 expression by RNA interference increases chemosensitivity to cisplatin in ovarian cancer cells, Reprod Sci, 22, 1618, 10.1177/1933719115590665